Pentixapharm Holding AG Logo

Pentixapharm Holding AG

Develops radiopharmaceuticals for diagnosing and treating oncology and adrenal disorders.

PTP | F

Overview

Corporate Details

ISIN(s):
DE000A383RV0 (+1 more)
LEI:
3912005VBOVXNDXEQZ36
Country:
Germany
Address:
Robert-Rössle-Straße, 10, 13125 Berlin
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pentixapharm Holding AG is a clinical-stage radiopharmaceutical development company that creates innovative, first-in-class compounds for both diagnostic and therapeutic applications. The company's pipeline primarily targets unmet medical needs in oncology, including hemato-oncology and solid tumors, as well as adrenal disorders. Key assets include two Phase III-ready drug candidates and a well-researched CXCR4-targeting compound. With a strong research and development focus, Pentixapharm has administered its compounds to over 2,000 patients in clinical settings.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 19:55
Earnings Release
Pentixapharm Holding AG: Pentixapharm significantly reduces projected loss for …
English 7.1 KB
2025-11-06 10:28
Director's Dealing
Pentixapharm Holding AG: Eckert Wagniskapital und Fruhphasenfinanzierung GmbH, …
English 6.4 KB
2025-11-03 10:52
Report Publication Announcement
English 3.9 KB
2025-10-23 22:12
Business and Financial Review
Pentixapharm Strengthens Pipeline Prioritization and Improves Cost Structure
English 8.6 KB
2025-10-23 20:59
Regulatory News Service
Pentixapharm Holding AG: Pentixapharm Focuses Development on Advanced Clinical …
English 7.5 KB
2025-10-06 11:00
Regulatory News Service
Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New …
English 10.5 KB
2025-09-26 08:00
Regulatory News Service
Pentixapharm Announces Advancement of PentixaTher to Fourth Dose Level in Acut…
English 11.3 KB
2025-09-16 15:19
Director's Dealing
Pentixapharm Holding AG: Eckert Wagniskapital und Fruhphasenfinanzierung GmbH, …
English 6.1 KB
2025-09-15 11:49
Director's Dealing
Pentixapharm Holding AG: Dr. Andreas Eckert, buy
English 5.8 KB
2025-08-06 00:00
Interim Report
Half-yearly financial report 2025
English 723.4 KB
2025-07-24 14:04
Report Publication Announcement
English 3.9 KB
2025-05-27 09:43
Regulatory News Service
Pentixapharm Holding AG: Pentixapharm outlines new clinical development strategy
English 10.0 KB
2025-05-08 00:00
Quarterly Report
Q1 statement / Q1 financial report 2025
English 479.2 KB
2025-04-26 16:00
Report Publication Announcement
English 3.8 KB
2025-04-25 00:00
Annual Report
Annual financial report 2024
English 2.3 MB

Automate Your Workflow. Get a real-time feed of all Pentixapharm Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pentixapharm Holding AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pentixapharm Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America AARD
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America ABBV
ABEONA THERAPEUTICS INC. Logo
Developing AAV-based cell and gene therapies for serious and rare diseases.
United States of America ABEO
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX

Talk to a Data Expert

Have a question? We'll get back to you promptly.